The global market for Indocyanine Green for Injection was estimated to be worth US$ 89.60 million in 2025 and is projected to reach US$ 148 million, growing at a CAGR of 7.2% from 2026 to 2032. Global Market Research Publisher QYResearch (QY Research) announces the release of its latest report “Indocyanine Green for Injection - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on 2025 market situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Indocyanine Green for Injection market, including market size, market share, market volume, demand, industry development status, and forecasts for the next few years. The report provides advanced statistics and information on global market conditions and studies the strategic patterns adopted by renowned players across the globe. As the market is constantly changing, the report explores competition, supply and demand trends, as well as the key factors that contribute to its changing demands across many markets. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/6706094/indocyanine-green-for-injection Indocyanine Green for Injection: Real-Time Fluorescence Imaging for Precision Surgery and Diagnostic Assessment 1. Product Definition and Core Characteristics Indocyanine Green for Injection is a sterile injectable diagnostic drug using indocyanine green as the active ingredient. It is typically supplied as a lyophilized powder for injection, often in 25 mg single-dose vials, with compatible diluent packaging or equivalent clinical single-dose formats. The product is mainly used for liver function and hepatic blood flow assessment, ophthalmic choroidal angiography, tissue perfusion evaluation, biliary visualization, lymphatic mapping, sentinel lymph node localization, and fluorescence-guided surgery. Its core value lies in providing real-time visualization of perfusion, vascular distribution, lymphatic flow, and anatomical structures, thereby supporting surgical decision-making and enhancing procedural safety across a growing range of clinical specialties. 2. Clinical Applications and Expanding Use Cases The clinical use of indocyanine green injection is expanding significantly beyond its traditional applications in liver function testing and ophthalmic angiography. Fluorescence-Guided Surgery: Helps surgeons identify biliary structures, assess tissue perfusion, evaluate anastomotic blood supply, map lymphatic drainage, and locate sentinel lymph nodes. These applications are particularly relevant in minimally invasive surgery, robotic-assisted surgery, and precision surgery, where real-time visualization improves procedural confidence and workflow efficiency. Key Surgical Specialties: General surgery, hepatobiliary surgery, gastrointestinal surgery, breast surgery, oncology surgery, vascular surgery, and transplant medicine are all adopting fluorescence-guided techniques. Diagnostic Applications: Liver function and hepatic blood flow assessment, ophthalmic choroidal angiography, and tissue perfusion evaluation in critical care and vascular medicine. The product's clinical workflow is clear, and although per-procedure usage volume is limited, recurring demand is relatively stable, supported by well-defined clinical use cases and high requirements for safety, supply stability, reconstitution convenience, and imaging consistency. 3. Market Size and Growth Dynamics The global Indocyanine Green for Injection market is showing steady growth, supported by continuous expansion of clinical applications. The market is projected to reach USD 0.15 billion by 2032, growing at a CAGR of 7.85% during the forecast period. This growth reflects demand moving beyond traditional liver function assessment and ophthalmic angiography into general surgery, hepatobiliary surgery, gastrointestinal surgery, breast surgery, oncology surgery, vascular surgery, and transplant medicine. As hospitals deploy more fluorescence imaging systems, endoscopic platforms, and robotic-assisted surgery systems, the clinical value of indocyanine green in intraoperative visualization, tissue perfusion assessment, biliary identification, lymphatic mapping, and sentinel lymph node localization becomes increasingly evident. 4. Industry Chain Analysis The value chain for indocyanine green injection spans from specialized upstream materials through midstream manufacturing to diverse downstream clinical settings. Upstream: Core materials include pharmaceutical-grade indocyanine green API, formulation excipients such as sodium iodide, water for injection, sterile glass vials, rubber stoppers, aluminum-plastic caps, lyophilized formulation packaging materials, light-protective packaging, and quality-control consumables. Because the product is sensitive to light, impurities, sterility control, and formulation stability, manufacturers require strong capabilities in aseptic lyophilized formulation, impurity control, content uniformity, container-closure integrity, and light-protected handling throughout the production process. Midstream: Production requires robust GMP systems, regulatory compliance, and comprehensive quality documentation for injectable diagnostic drugs. Value is concentrated in the ability to consistently produce sterile, stable, and reliable product meeting pharmacopoeia standards across multiple markets. Downstream: Customers include general hospitals, ophthalmology hospitals, hepatobiliary surgery departments, gastrointestinal surgery departments, oncology surgery departments, vascular surgery departments, transplant centers, breast surgery departments, ambulatory surgery centers, and pharmaceutical distribution channels. Hospital demand is closely linked to the installed base of fluorescence imaging systems, endoscopic platforms, robotic surgery systems, and physician adoption of fluorescence-guided workflows. 5. Competitive Landscape The global market for Indocyanine Green for Injection features a concentrated competitive landscape with a limited number of specialized manufacturers. Global key manufacturers include Diagnostic Green and Daiichi Sankyo, among others. The top three players collectively held approximately 56.2% market share in 2025, reflecting the specialized nature of the product and the significant barriers to entry in sterile injectable manufacturing and regulatory compliance. The market remains characterized by high requirements for quality consistency, supply reliability, and regulatory expertise. Companies with established manufacturing capabilities, regional approvals, and hospital channel coverage are positioned to capture specialized growth opportunities as clinical applications continue to expand. 6. Technology Evolution and Clinical Workflow Integration Indocyanine green injection is evolving from an auxiliary diagnostic drug into a practical perioperative visualization tool, driven by broader trends in surgical practice. Traditional Diagnostic Use: Liver function assessment using ICG clearance testing and ophthalmic choroidal angiography remain established applications with standardized protocols. Fluorescence-Guided Surgery: The major growth vector, with ICG used intraoperatively in conjunction with near-infrared fluorescence imaging systems to provide real-time anatomical and perfusion information. Minimally Invasive and Robotic Surgery: As these techniques become more prevalent, the demand for real-time visualization tools that enhance procedural safety without adding significant complexity continues to rise. Product Improvement Direction: Development efforts focus on higher purity, stronger formulation stability, easier reconstitution, better compatibility with imaging systems, and more standardized clinical workflows. Guideline Development: Accumulation of multi-specialty guidelines, hospital training programs, and real-world clinical experience is supporting broader adoption in ambulatory surgery, robotic surgery, and specialty minimally invasive procedures. 7. Growth Drivers Several fundamental factors are driving sustained growth in the indocyanine green injection market. Aging Populations and Disease Burden: Increasing diagnostic and treatment needs for oncology, vascular, hepatobiliary, and digestive diseases are supporting procedural demand across multiple surgical specialties. Emphasis on Surgical Safety: Hospitals are placing greater emphasis on perfusion assessment, intraoperative visualization, and risk reduction, expanding the role of fluorescence-guided applications in routine surgical practice. Imaging System Proliferation: Growing installed base of fluorescence imaging systems, endoscopic platforms, and robotic-assisted surgery systems creates the infrastructure necessary for ICG adoption. Clinical Evidence Accumulation: Expanding body of clinical literature and specialty society guidelines supporting fluorescence-guided techniques builds physician confidence and encourages adoption. Cross-Specialty Collaboration: Stronger collaboration among imaging equipment suppliers, hospital departments, and pharmaceutical companies is helping indocyanine green transition from an optional auxiliary product to a routine tool in selected high-value procedures. Recurring Demand: Although per-procedure usage is limited, the product has clear clinical use cases generating relatively stable recurring demand in hospitals with established fluorescence imaging programs. 8. Barriers and Challenges The industry faces several constraints that shape competitive dynamics and market access. Regulatory Compliance Requirements: As a sterile injectable product, indocyanine green injection requires strict control over API purity, impurity profile, lyophilized stability, light-protective packaging, and sterility assurance. New entrants face long registration review timelines, quality-system requirements, and hospital access cycles. Pricing Pressure and Reimbursement: Regional reimbursement policies, hospital procurement pricing, and potential generic competition may affect profitability, particularly as the product becomes more widely used. Clinical Education Requirements: Clinical penetration depends not only on drug availability but also on the installed base of fluorescence imaging systems, physician training, departmental education, and procedural standardization. Device Compatibility: The product's clinical utility is inherently linked to the availability and compatibility of fluorescence imaging equipment, creating an interdependent adoption dynamic. Manufacturing Complexity: Lyophilized sterile injectable manufacturing requires specialized facilities, equipment, and expertise, limiting the number of qualified suppliers. 9. Future Outlook The future development of indocyanine green for injection will be closely linked to the broader adoption of precision surgery, minimally invasive procedures, and fluorescence-guided navigation. In the short term, demand will be anchored by expanding use in hepatobiliary surgery, gastrointestinal surgery, breast surgery, and oncology surgery, supported by growing hospital investment in fluorescence imaging capabilities. In the medium to long term, as surgeons place greater emphasis on real-time visualization, tissue boundary identification, and intraoperative risk control, indocyanine green injection is expected to evolve into a routine perioperative tool across an increasing number of surgical specialties. Adoption in ambulatory surgery, robotic surgery, and specialty minimally invasive procedures is expected to increase as guidelines mature and clinical experience accumulates. Product development will focus on higher purity formulations, enhanced stability, simplified reconstitution, and better integration with advanced imaging platforms. For vendors, competitive advantage will depend on quality consistency, regulatory expertise across multiple markets, clinical education and training support, hospital channel coverage, and effective collaboration with imaging equipment manufacturers to create integrated solutions for fluorescence-guided surgery. Companies with stable quality systems, regional approvals, and strong hospital relationships are best positioned to capture the specialized growth opportunities in this evolving market. The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively. The Indocyanine Green for Injection market is segmented as below: By Company Diagnostic Green Daiichi Sankyo Nanjing Chia Tai Tianqing Pharmaceutical Dandong Yichuang Pharmaceutical Segment by Type 25 mg/Vial 50 mg/Vial Segment by Application Hospitals Specialty Clinics Other Each chapter of the report provides detailed information for readers to further understand the Indocyanine Green for Injection market: Chapter 1: Introduces the report scope of the Indocyanine Green for Injection report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032) Chapter 2: Detailed analysis of Indocyanine Green for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026) Chapter 3: Provides the analysis of various Indocyanine Green for Injection market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032) Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032) Chapter 5: Sales, revenue of Indocyanine Green for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032) Chapter 6: Sales, revenue of Indocyanine Green for Injection in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032) Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026) Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry. Chapter 9: Conclusion. Benefits of purchasing QYResearch report: Competitive Analysis: QYResearch provides in-depth Indocyanine Green for Injection competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge. Industry Analysis: QYResearch provides Indocyanine Green for Injection comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis. and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions. Market Size: QYResearch provides Indocyanine Green for Injection market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development. Other relevant reports of QYResearch: Global Indocyanine Green for Injection Market Research Report 2026 Global Indocyanine Green for Injection Market Outlook, In‑Depth Analysis & Forecast to 2032 Global Indocyanine Green for Injection Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032 To contact us and get this report: https://www.qyresearch.com/contact-us About Us： QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp